We are a biotech royalty aggregator

with 70+ assets and growing.

XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

Royalty Portfolio

We have an expansive portfolio of licenses that provides us the right to future potential royalty and milestone payments.  The drug candidate assets underlying the licenses are being developed by others. 

Royalty Acquisition

We are actively acquiring the rights to future potential milestone and royalty payments to pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies.  

Investor Relations

We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a capital-efficient structure to strive to deliver shareholder value.    

Register for News Updates:

Subscribe to our company news email list and receive XOMA news as it is released. To protect your privacy, your email address will be used only for this news distribution list.

March 2024
March 2024

Download our latest presentation:

DOWNLOAD NOW »

Register for News Updates:

Subscribe to our company news email list and receive XOMA news as it is released. To protect your privacy, your email address will be used only for this news distribution list.

Meet XOMA's Executive Leadership Team:

Meet XOMA's Executive Leadership Team:

Play Video

XOMA: The royalty aggregator that thinks like a biotech

April 16, 2021

Non-Dilutive, Non-Recourse Financing Backed by VABYSMO® Royalties

December 19, 2023

October 7, 2021
See the latest Iscalimab update from the Novartis December R&D Day

Latest News